Free Trial
NYSEAMERICAN:OSTX

OS Therapies Q4 2025 Earnings Report

OS Therapies logo
$1.76 +0.04 (+2.02%)
As of 03:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OS Therapies EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OS Therapies Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
7:00AM ET

OS Therapies Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

View OS Therapies Profile